Patents Examined by Lora E Barnhart
-
Patent number: 8883495Abstract: The present invention has objects to provide a novel human T-cell population having both cytotoxic and immunosuppressive activities, and to a method for preparing the same. The above objects are attained by providing a human T-cell population which is obtainable by coculturing mononuclear cells, collected from human blood, with stroma cells and which has the following features: (1) being positive for CD3, CD25, CD28 and T-cell antigen receptor ??; (2) essentially consisting of three groups of a CD4 positive and CD8 positive (CD4+CD8+) T-cell group, a CD4 positive and CD8 dimly positive (CD4+CD8dim) T-cell group, and a CD4 negative and CD8 positive (CD4?CD8+) T-cell group; (3) exerting a cytotoxic activity against the cocultured stroma cells; and (4) exerting an immunosuppressive activity against activated T cells.Type: GrantFiled: March 15, 2007Date of Patent: November 11, 2014Assignee: Hayashibara Co., Ltd.Inventors: Shuji Nakamura, Ryuichi Motoda, Masayoshi Kibata, Kunzo Orita, Fumiyuki Yamasaki
-
Patent number: 8877181Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: November 4, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S Marshall, Richard A Banas
-
Patent number: 8871198Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: March 14, 2007Date of Patent: October 28, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8859853Abstract: Artificial seeds formed of a seamless soft capsule are provided herein. The artificial seed contains a meristematic plant cell or tissue. The artificial seed has a structure of three or more layers containing an innermost layer, an inner layer covering the innermost layer, and an outer layer covering the inner layer. The innermost layer can contain an aqueous liquid, the inner layer can be formed by an inner membrane containing hardened oil, and the outer layer can be formed of a biodegradable outer membrane.Type: GrantFiled: August 24, 2005Date of Patent: October 14, 2014Assignee: Morishita Jintan Co., LtdInventors: Masanori Asada, Yumi Hatano, Ryosei Kamaguchi, Hideki Sunohara
-
Patent number: 8834862Abstract: Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of a pharmaceutical agent are described.Type: GrantFiled: April 19, 2005Date of Patent: September 16, 2014Assignee: NanoCyte Inc.Inventors: Tamar Lotan, Shimon Eckhouse
-
Patent number: 8815539Abstract: Melanin or inorganic fertilizers are produced from fermentation leachates or from low-cost nutrient-rich solutions. The method for producing the melanin or inorganic fertilizer comprises repetitive trophic cycling in the controlled conditions of primary and secondary bioreactors. Nutrients are cycled between microorganisms such as bacteria, yeast and fungi and black soldier fly larvae, Hermetia illucens. Polysaccharides are partly converted into natural melanins or inorganic fertilizer, which are difficult to biodegrade and hence accumulate in the bioreactors. The method can employ, as a source of nutrients, leachates produced from food waste or from sugar-rich liquid waste of the food industry. These leachates can be used raw or can be augmented with low-cost sugar-rich solutions such as molasses, hydrolyzed cellulose or starch. The method is inexpensive and does not require the use of expensive chemically-defined culture media.Type: GrantFiled: June 6, 2013Date of Patent: August 26, 2014Assignee: River Road Research, Inc.Inventors: Radu Popa, Kenneth H. Nealson
-
Patent number: 8815557Abstract: Compounds and methods for refolding of proteins in an aqueous solution. In particular, biocompatible multiblock copolymer surfactants such as poloxamers, meroxapols, poloxamines, or polyols are used to catalyze proper refolding without changing the protein composition, and restore the protein to its native conformation and native biological function. The methods can be practiced both in vivo and in vitro. The biocompatible multiblock copolymer surfactants can be used for renaturation of recombinantly expressed proteins, and for renaturation of proteins that are unfolded due to heat, irradiation, mechanical shearing, electrical shock, frostbite, chemical stress, and other abiotic or biotic stresses.Type: GrantFiled: July 10, 2006Date of Patent: August 26, 2014Assignee: University of ChicagoInventors: Raphael C. Lee, Annie Kuo, Hanne Gissel Hyldkrog, Florin Despa, Devkumar Mustafi
-
Patent number: 8796025Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: May 8, 2012Date of Patent: August 5, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8784889Abstract: Described are devices, methods, and systems for grafting tissues or organs that are exposed to bacterial or mammalian enzymes that degrade collagenous materials. Illustrative medical grafts are processed by contacting a collagenous extracellular matrix (ECM) material with a mono-carboxylic acid having from four to about twelve carbon atoms, or mixtures of two or more such acids.Type: GrantFiled: January 30, 2007Date of Patent: July 22, 2014Assignee: Cook Biotech IncorporatedInventors: Jason P. Hodde, David M. J. Ernst
-
Patent number: 8759030Abstract: The object of the present invention is to provide a method and a process for producing 2-O-?-glucopyranosyl-L-ascorbic acid where 5-O-?-glucopyranosyl-L-ascorbic acid and 6-O-?-glucopyranosyl-L-ascorbic acid are not formed or formed in such a small amount that the formation of these can nor be detected. The present invention solves the above object by providing a process for producing 2-O-?-glucopyranosyl-L-ascorbic acid comprising the steps of allowing ?-isomaltosyl glucosaccharide-forming enzyme together with or without cyclomaltodextrin glucanotransferase (EC 2.4.1.19) to act on a solution comprising L-ascorbic acid and, an ?-glucosyl saccharide to form 2-O-?-glucopyranosyl-L-ascorbic acid and collecting the formed 2-O-?-glucopyranosyl-L-ascorbic acid.Type: GrantFiled: July 7, 2003Date of Patent: June 24, 2014Assignee: Hayashibara Co., Ltd.Inventors: Kazuhisa Mukai, Keiji Tsusaki, Michio Kubota, Shigeharu Fukuda, Toshio Miyake
-
Patent number: 8748177Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.Type: GrantFiled: March 30, 2011Date of Patent: June 10, 2014Assignee: The Hospital for Sick ChildrenInventors: Freda Miller, David Kaplan, Kristen Smith, Maryline Paris, Sibel Naska
-
Patent number: 8741646Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 6, 2011Date of Patent: June 3, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Vivienne S Marshall
-
Patent number: 8741635Abstract: The present invention relates generally to a method for the generation of a substantially homogenous population of undifferentiated cells. More particularly, the present invention relates to a method for isolating a substantially homogenous population of stem cells, and in particular, mammary stem cells (MaSCs). The MaSCs of the present invention are isolated on the basis of differential levels of proteins present on their cell surface. The MaSCs of the present invention are particularly useful as targets for identifying agents which modulate MaSC survival, self-renewal, proliferation and/or differentiation in both normal and diseased tissue such as, but not limited to, tumor tissue, and, also as source of tissue for the regeneration, replacement and/or augmentation of tissue damaged and/or lost after disease or injury.Type: GrantFiled: May 12, 2005Date of Patent: June 3, 2014Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Geoffrey John Lindeman, Mark Shackleton, Francois Vaillant, Jane Ellen Visvader
-
Patent number: 8728743Abstract: The invention concerns micro-organism strains, in particular of lactic acid bacteria, having a glycosylation modulating effect of intestinal cell surface. The invention also concerns a method for selecting micro-organism strains, in particular of lactic acid bacteria, which consists in measuring the average fluorescence intensity variation of HT29-MTX cells incubated in the presence of a lectin coupled with a fluorochrome after being in contact with the supernatant of the strain concerned. Said lactic acid bacteria strains can be used, optionally in the form of their active fraction, for preparing food compositions or medicines or food supplements, modulating glycosylation of glycoproteins of intestinal epithelial cells.Type: GrantFiled: November 16, 2005Date of Patent: May 20, 2014Assignee: Compagnie Gervais DanoneInventors: Jean-Michel Antoine, Miguel Freitas, Chantal Cayuela, Germain Trugnan
-
Patent number: 8728752Abstract: The present invention relates to a method for the detection of essentially intact encapsulated or non-encapsulated parasites in meat, comprising the maceration of the meat with an alkaline digestion solution which contains a digestive enzyme that is active in an alkaline environment. Further, uses of a serine endopeptidase in a method for the detection of essentially intact encapsulated or non-encapsulated parasites in meat are described. The present invention also describes serine endopeptidases for use in a diagnostic method for the detection of essentially intact encapsulated or non-encapsulated parasites in meat. Finally, a kit is disclosed which comprises the enzymes and alkaline digestion solutions of the present invention.Type: GrantFiled: June 21, 2010Date of Patent: May 20, 2014Inventor: Philipp Bauer
-
Patent number: 8709402Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: April 29, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S Marshall
-
Patent number: 8709400Abstract: Provided herein is an approach to establish organogenetic tolerance via prior transplantation of pig embryonic pancreas, thereby enabling subsequent implantation of porcine islets in a subject without the need for immune-suppression. In one aspect of the invention, porcine pancreatic primordia are implanted into a mammalian subject, and after a period of time sufficient to induce tolerance, porcine islet cells are implanted in the subject.Type: GrantFiled: July 26, 2010Date of Patent: April 29, 2014Assignee: Washington UniversityInventor: Marc Hammerman
-
Patent number: 8691523Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: GrantFiled: December 12, 2006Date of Patent: April 8, 2014Assignees: Vesta Therapeautics, Inc., University of North Carolina at Chapel HillInventors: Lola M. Reid, Nicholas Moss, Mark E. Furth, John W. Ludlow, Andrew T. Bruce
-
Patent number: 8685390Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: April 1, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S. Marshall
-
Patent number: 8652530Abstract: The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.Type: GrantFiled: May 15, 2013Date of Patent: February 18, 2014Assignee: Cartilast Corp.Inventor: Eugene R. Moore